OC
CPRX

Oppenheimer & Co’s Catalyst Pharmaceutical CPRX Stock Holding History

Oppenheimer & Co’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-68,116
Closed -$1.69M – 1783
2026
Q1 		$1.69M Sell
68,116
-38,862
-36% -$926K 0.02% 657
2025
Q4 		$2.5M Buy
106,978
+15,001
+16% +$334K 0.04% 480
2025
Q3 		$1.81M Sell
91,977
-11,293
-11% -$232K 0.02% 642
2025
Q2 		$2.24M Buy
103,270
+4,524
+5% +$107K 0.03% 537
2025
Q1 		$2.39M Sell
98,746
-5,741
-5% -$129K 0.04% 493
2024
Q4 		$2.18M Buy
104,487
+23,078
+28% +$496K 0.03% 513
2024
Q3 		$1.62M Sell
81,409
-5,314
-6% -$98.5K 0.02% 616
2024
Q2 		$1.34M Buy
86,723
+36,192
+72% +$563K 0.02% 660
2024
Q1 		$805K Buy
+50,531
New +$761K 0.01% 818

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Oppenheimer & Co's CPRX Position: Q2 2026 in Review

Oppenheimer & Co sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 68,116 shares — an estimated $1.69M sold.

Oppenheimer & Co first reported a position in CPRX in Q1 2024 and held it in 9 quarters. The position peaked at $2.5M in Q4 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Oppenheimer & Co reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Oppenheimer & Co sold 68,116 Catalyst Pharmaceutical shares in Q2 2026, an estimated $1.69M.
  • Oppenheimer & Co first reported a position in Catalyst Pharmaceutical in Q1 2024 and held it in 9 quarters.
  • Oppenheimer & Co's Catalyst Pharmaceutical position peaked at $2.5M in Q4 2025.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.